-

07:26:23 AM

LIVE Real Time KDNY Stock Market News

KDNY - Chinook Therapeutics Inc

04/15/21 8:15 AM

Nasdaq : KDNY

Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021

Poster presentation on BION-1301 including Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and 2 of the ongoing phase 1b study of BION-1301 and data from the phase 1 IV to SC bioavailability study in healthy volunteers Poster presentation on atrasentan's effect to rapidly reduce

RHEA-AI

neutral

04/08/21 4:30 PM

Nasdaq : KDNY

Chinook Therapeutics to Present at Upcoming Investor Conferences

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in the

RHEA-AI

neutral

04/07/21 4:05 PM

Nasdaq : KDNY

Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the full

RHEA-AI

neutral

04/07/21 8:15 AM

Nasdaq : KDNY

Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for

RHEA-AI

neutral

04/05/21 8:15 AM

Nasdaq : KDNY

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical

RHEA-AI

positive

04/01/21 4:15 PM

Nasdaq : KDNY

Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation

RHEA-AI

very positive

03/30/21 4:26 PM

Nasdaq : KDNY

Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress

Key presentations for BION-1301 at the ISN World Congress of Nephrology 2021 in April include Gd-IgA1 biomarker data in healthy volunteers from Parts 1 and Part 2 of the ongoing phase 1 study of BION-1301, as well as data from the phase 1 IV to SC bioavailability study in healthy volunteers Small

RHEA-AI

neutral

03/16/21 8:15 AM

Nasdaq : KDNY

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the

RHEA-AI

neutral

03/02/21 4:15 PM

Nasdaq : KDNY

Chinook Therapeutics to Present at Upcoming Investor Conferences

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is

RHEA-AI

neutral

03/01/21 8:15 AM

Nasdaq : KDNY

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases

Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec's PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient Stratification Strategies in Kidney Disease Collaboration Will Focus on Polycystic Kidney Disease

RHEA-AI

very positive